1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

MPN - 120

RALLY-MF: Initial Efficacy of a Phase 2 Study of DISC-0974, an Anti-Hemojuvelin Antibody, to Treat Anemia in Myelofibrosis

Naseema Gangat

Poster Presenter: Naseema Gangat

MM - 218

Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis

Giada Bianchi

Poster Presenter: Giada Bianchi

$Thumbnail for Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): First Real-World Data From the Center for International Blood and Marrow Transplant Research (CIBMTR)$

CT - 230

Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): First Real-World Data From the Center for International Blood and Marrow Transplant Research (CIBMTR)

Elise Chong

Poster Presenter: Elise Chong

Thumbnail for Updated Clinical Data From the Phase 1 Study of Dibotatug (DR-01), a Nonfucosylated Anti-CD94 Antibody, in Patients With Large Granular Lymphocytic Leukemia

TCL - 418

Updated Clinical Data From the Phase 1 Study of Dibotatug (DR-01), a Nonfucosylated Anti-CD94 Antibody, in Patients With Large Granular Lymphocytic Leukemia

Tapan Kadia

Poster Presenter: Tapan Kadia

Thumbnail for Primary Outcomes from the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)

ABCL - 489

Primary Outcomes from the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)

Jason Westin

Poster Presenter: Jason Westin

Video

Thumbnail for Updated Results From the Phase 3 ECHO Trial of Bendamustine-Rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: 50 Months of Follow-up

MCL - 575

Updated Results From the Phase 3 ECHO Trial of Bendamustine-Rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: 50 Months of Follow-up

Michael Wang

Poster Presenter: Michael Wang

$Thumbnail for Safety and Preliminary Efficacy of Olverembatinib (HQP1351) Combined With Lisaftoclax (APG-2575) in Children and Adolescents With Relapsed/Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: Results of a Phase 1b Study$

ALL - 584

Safety and Preliminary Efficacy of Olverembatinib (HQP1351) Combined With Lisaftoclax (APG-2575) in Children and Adolescents With Relapsed/Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: Results of a Phase 1b Study

Jeffrey Rubnitz

Poster Presenter: Jeffrey Rubnitz

Thumbnail for ENABLE: A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients With Previously Treated CP-CML

CML - 652

ENABLE: A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients With Previously Treated CP-CML

Fadi G Haddad

Poster Presenter: Fadi G Haddad

$Thumbnail for Ofirnoflast (HT-6184), a First-in-Class Allosteric NEK7 Inhibitor, Achieves Durable Transfusion Independence (TI) and Hematological Improvement-Erythroid (HI-E) in ESA-Refractory Lower-Risk Myelodysplastic Syndrome (LR-MDS): Phase 2 Final Results$

MDS - 812

Ofirnoflast (HT-6184), a First-in-Class Allosteric NEK7 Inhibitor, Achieves Durable Transfusion Independence (TI) and Hematological Improvement-Erythroid (HI-E) in ESA-Refractory Lower-Risk Myelodysplastic Syndrome (LR-MDS): Phase 2 Final Results

Amit Verma

Poster Presenter: Amit Verma